| 參考文獻 |
中文部份
方至民、鍾憲瑞（民95），策略管理，前程。
全民健康保險降血脂藥物給付規定表。
何饒通等（民92），高血脂防治手冊，行政院衛生署國民健康局。
吳造中（民94），台灣介入性醫學會年會報告。
李吉仁、陳振祥（民93），企業概論，華泰。
林建煌（民94），行銷管理，華泰。
榮泰生（民94），行銷學，五南。
樓永堅、方世榮（民95），行銷管理學，東華。
鄭華清（民96），行銷管理，全華科技。
蕭富峰（民96），行銷管理，智勝。
英文部分
A Booz (1982), New Product Management for the 1980s, Allen & Hamilton Inc.,
New York.
DA Aaker, JG Shansby (1982), "Positioning your product", Business Horizons.
Fergus McTaggart, Linda Buckett, Robert Davidson, Geoffry Holdgate, Alex
McCormick, Dennis Schneck, Graham Smith, and Michael Warwick (2001),
“Preclinical and Clinical Pharmacology of Rosuvastatin, a New
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor”, Am J Cardiol,
87, p28B-32B
G Armstrong, P Kotler (2006), Marketing Management, Pearson/Prentice Hall Upper
Saddle River, NJ.
Herbert Schuster & Jonathan C Fox (2004), “Investigating cardiovascular risk
reduction- the Rosuvastatin GALAXY Programme”, Exper Opin.
Pharmacother, 5(5), p1187-1200
J Farell, S Scotchmer (1988), "Partnerships", Quarterly Journal of Economics.
JF Engel, MR Warshaw, TC Kinnear (1983), Promotional s trategy, Homewood,
Illinois.
John C. LaRosa, Scott M. Grundy, David D. Waters, Charles Shear, Philip Barter,
Jean-Charles Fruchart, Antonio M. Gotto, D.Phil., Heiner Greten, John J.P.
Kastelein, James Shepherd, Nanette K. Wenger (2005), “Intensive Lipid
Lowering with Atorvastatin in Patients with Stable Coronary Disease”, New
England Journal of Medicine, 352, p1425-1435
JP Maggard(1976), "Is Positioning Old, New, or Borrowed?", Journal of Marketing.
Neil J. Stone, Luther T. Clark, Donald B. Hunninghake, Richard C. Pasternak, Sidney
C. Smith, Jr, Scott M. Grundy, James I. Cleeman, C. Noel Bairey Merz, H.
Bryan Brewer, Jr (2004), “American Implications of Recent Clinical Trials for
the National Cholesterol Education Program Adult Treatment Panel III
Guidelines”, Circulation, 110, p227-239
P Drucker(1973), Management: Tasks, Perspectives, Practices, Heinemann, Londres.
Peter H. Jones, Michael H. Davidson, Evan A. Stein, Harold E. Bays, James M.
McKenney, Elinor Miller, Valerie A. Cain, and James W. Blasetto (2003),
“Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin,
Simvastatin, and Pravastatin Across Doses (STELLAR* Trial)”, Am J Cardiol,
92, p152-160
Peter H. Jones, Michael H. Davidson, Evan A. Stein, Harold E. Bays, James M.
McKenney, Elinor Miller, Valerie A. Cain, and James W. Blasetto, Brewer HB
(2003), “Benefit-risk assessment of Rosuvastatin 10mg to 40mg. Comparison
of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and
Pravastatin Across Doses (STELLAR* Trial)”, Am J Cardiol, 92, p23K-29K
Schuster H, Barter P, Stender S et al. (2004), “Effects of Switching Statins on
Achievement of Lipid Goals: Measuring Effective Reductions in Cholesterol
Using Rosuvastatin Therapy (Mercury I) study”, American Heart Journal, 147,
p705-712
T Schneeweis, R Spurgin, D McCarthy (1996), Survivor bias in commodity trading
advisor performance, Journal of Futures Markets.
W Smith (1956), The Long Trail to Battle, Collins.
W Yoram (1978), "Issues and Advances in Segmentation Research", Journal of
Marketing Research, New York.
WJ Keegan (2002), Global Marketing Management, Prentice-Hall: Upper Saddle
River, NJ.
網站部份
Intercontinental Marketing Services，http://www.imiresearch.com/。
Mckinsey Market Research，http://www.mckinsey.com/。
中華民國開發性製藥研究協會，http://www.irpma.org.tw/。
行政院衛生署死因摘要統計，http://www.doh.gov.tw/statistic/data/死因摘要/94年/94.htm。 |
[Endnote RIS 格式]
[相關文章]
[文章引用]
[完整記錄]
[館藏目錄]
至系統瀏覽論文 ( 永不開放)
plurk
funp
live
udn
HD
myshare
netvibes
friend
youpush
delicious
baidu
Google bookmarks
del.icio.us
hemidemi
facebook
twitter
google
reddit